The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Medscape; MSD Oncology; Novartis; Oncohost; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Abion; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Mirati Therapeutics; MSD Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Merck
 
Heather A. Wakelee
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst); Xcovery (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck
 
Jonathan Spicer
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb/Medarex; Chemocentryx; Merck; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck; Protalix Biotherapeutics; Regeneron; Xenetic Biosciences
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Medarex (Inst); CLS-Therapeutics (Inst); CLS-Therapeutics (Inst); Merck (Inst); Protalix Biotherapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck
 
Moishe Liberman
Stock and Other Ownership Interests - AssistIQ; Ditch Labs; Endocision
Consulting or Advisory Role - Johnson and Johnson
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Sanofi (Inst); Cook Medical (Inst); Ethicon/Johnson & Johnson (Inst); Johnson & Johnson/MedTech (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Cryobiopsy Device
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; DaiichiSankyo; Janssen; Merck KGaA; MSD; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer; BeiGene (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); Janssen (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst)
 
Masahiro Tsuboi
Honoraria - Amgen KK; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb KK (Inst); Johnson & Johnson/Eticon (Inst); Merck (Inst); MiRXES (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Lilly; Merck Sharp & Dohme; Roche; Yuhan
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abion
Research Funding - AstraZeneca (Inst); Lunit (Inst); Merck Sharp & Dohme (Inst)
 
Ke-Neng Chen
Research Funding - MSD (Inst)
 
Christophe Alfons Dooms
Consulting or Advisory Role - MSD Oncology (Inst)
Travel, Accommodations, Expenses - MSD (Inst)
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche
 
Ekkehard Eigendorff
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Research Funding - MSD (Inst)
 
Gastón L. Martinengo
Research Funding - MSD (Inst)
 
Olivier Bylicki
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; Janssen Oncology; MSD; Roche; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; MSD Oncology
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - MSD; Roche
 
Jamie E. Chaft
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca/MedImmune; Bristol-Myers Squibb; Flame Biosciences; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Jing Yang
Employment - Merck
 
Ashwini Arunachalam
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Josephine M Norquist
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Steven M. Keller
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Shugeng Gao
Research Funding - MSD (Inst)